Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Nicole Vitullo

AddedApr 2, 2024

UpdatedMay 31, 2026

Nicole Vitullo

Nicole Vitullo

Board Member, BioScience Managers

Crunchbase LinkedIn

Nicole Vitullo's Career

BioScience Managers

BioScience Managers

Melbourne, Victoria, AU

Board Member· Board

Marinus Pharmaceuticals

Marinus Pharmaceuticals

Radnor, PA, US

Board Member· Board

Esperion Therapeutics Esper

Esperion Therapeutics Esper

Ann Arbor, MI, US

Board Member· Board

Celtaxsys

Atlanta, GA, US

Board Member· Board

Allay Therapeutics

Allay Therapeutics

Menlo Park, CA, US

Board Member· Board

Antios Therapeutics

Antios Therapeutics

Atlanta, GA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Nicole Vitullo's Career

BioScience Managers

BioScience Managers

Investment FirmInvestment Firm302003Melbourne, Victoria, AU

Board Member· Board

Leadership at BioScience Managers

Matt McNamaraBoard Member

Dennis PurcellBoard Member

Jeremy Curnock CookBoard Member

Alan CaineyBoard Member

Jonathan HeppleCo-Founder

Jonathan BuckleyCo-Founder

Marinus Pharmaceuticals

Marinus Pharmaceuticals

Public$406.9M1512003Radnor, PA, US

Board Member· Board

Leadership at Marinus Pharmaceuticals

Elan EzicksonBoard Member

Harry H. PennerFounder

Tim MaylebenBoard Member

Seth FischerBoard Member

Scott BraunsteinBoard Member

Harry T ReinBoard Member

Similar to Marinus Pharmaceuticals

Supernus PharmaceuticalsRockville, MD, USPharmaceuticalsest. 2005Supernus PharmaceuticalsRockville, MD, US · est. 2005

US-based Supernus Pharmaceuticals develops and markets proprietary drugs for central nervous system disorders.

Public · $689.5M612

Marius PharmaceuticalsRaleigh, NC, USPharmaceuticalsest. 2017Marius PharmaceuticalsRaleigh, NC, US · est. 2017

Marius Pharmaceuticals: A biopharmaceutical firm innovating patient-centric therapies for hypogonadism.

Series A · $32.6M19

Sea PharmaceuticalsCambridge, MA, USPharmaceuticalsest. 2013Sea PharmaceuticalsCambridge, MA, US · est. 2013

Sea Pharmaceuticals develops innovative oral treatments for neurological disorders like tinnitus and epilepsy.

AptinyxEvanston, IL, USPharmaceuticalsest. 2015AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12

Esperion Therapeutics Esper

Esperion Therapeutics Esper

Public1992008Ann Arbor, MI, US

Board Member· Board

Leadership at Esperion Therapeutics Esper

Jay ShepardBoard Member

Mike PapeFounder

Sheldon KoenigBoard Member

Stephen RocamboliBoard Member

J. Martin CarrollBoard Member

Dr Antonio M Gotto JrBoard Member

Similar to Esperion Therapeutics Esper

Lipidio PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2018Lipidio PharmaceuticalsSan Diego, CA, US · est. 2018

Lipidio Pharma: Advancing molecules for dermatological and metabolic diseases treatment.

Series A · $20M5

HDL TherapeuticsVero Beach, FL, USCardiovascular, Therapeuticsest. 2009HDL TherapeuticsVero Beach, FL, US · est. 2009

HDL Therapeutics: FDA-approved biotech firm specializing in cardiovascular disease treatment.

Public · $10.8M6

Elicio TherapeuticsCambridge, MA, USPharmaceuticalsest. 2011Elicio TherapeuticsCambridge, MA, US · est. 2011

Elicio: A pharmaceutical research firm dedicated to re-engineering immune responses to cancer.

Public · $222.3M38

Chesapeake TherapeuticsPikesville, MD, USMedicationsest. 2014Chesapeake TherapeuticsPikesville, MD, US · est. 2014

Chesapeake Therapeutics: Developing tailored medications for children's rheumatic diseases.

Pre-Seed · $1.3M5

Celtaxsys

Public$65.2M112007Atlanta, GA, US

Board Member· Board

Leadership at Celtaxsys

Khalil BarrageBoard Member

H. Daniel PerezBoard Member

Bill ReddickFounder

Gerry BrunkBoard Member

Maxim GorbachevBoard Member

Rick EiswirthBoard Member

Similar to Celtaxsys

Cellix BioNewark, NJ, USMedical Researchest. 2013Cellix BioNewark, NJ, US · est. 2013

Cellix Bio: Advancing medical research for enhanced drug development and faster recovery in immune diseases.

Series A · $14.3M30

ComplexaPittsburgh, PA, USTherapeuticsest. 2008ComplexaPittsburgh, PA, US · est. 2008

Complexa, Inc.: A biopharmaceutical firm innovating therapies for inflammatory and metabolic diseases.

Public · $86.9M7

CelnyxDestin, FL, USBiotechnologyest. 2009CelnyxDestin, FL, US · est. 2009

Destin-based biotech company, Celnyx, innovating in biotechnology industry.

Celsius TherapeuticsCambridge, MA, USTherapeuticsest. 2018Celsius TherapeuticsCambridge, MA, US · est. 2018

Celsius Therapeutics, a US-based biotech firm, develops drugs for cancer and autoimmune diseases.

Series B · $148M72

Allay Therapeutics

Allay Therapeutics

Series C$118.9M562017Menlo Park, CA, US

Board Member· Board

Leadership at Allay Therapeutics

Adam GridleyCEO

Josh MakowerBoard Member

Hanson GiffordFounder

Similar to Allay Therapeutics

Allyx TherapeuticsNew Haven, CT, USTherapeuticsest. 2018Allyx TherapeuticsNew Haven, CT, US · est. 2018

Allyx Therapeutics: Clinical-stage biotech firm developing therapies to combat Alzheimer's disease.

Seed · $10.1M4

Amalgent TherapeuticsChapel Hill, NC, USPain Medicationsest. 2020Amalgent TherapeuticsChapel Hill, NC, US · est. 2020

Amalgent Therapeutics: Innovating safer, effective analgesia alternatives to opioids since 2020.

Angel · $450k2

DoloromicsMenlo Park, CA, USBiomarkers, Pain Therapeuticsest. 2020DoloromicsMenlo Park, CA, US · est. 2020

Doloromics: A Dallas-based company innovating in pain therapeutics discovery and disease-specific solutions.

Concentric AnalgesicsSan Francisco, CA, USTherapeuticsest. 2014Concentric AnalgesicsSan Francisco, CA, US · est. 2014

Concentric Analgesics, Inc.: A biotech firm innovating non-opioid solutions for acute and chronic pain.

Series B · $103.1M22

Antios Therapeutics

Antios Therapeutics

Public$200.4M352018Atlanta, GA, US

Board Member· Board

Leadership at Antios Therapeutics

Henry ChenBoard Member

Idean MarvastyCo-Founder

Abel De La RosaBoard Member

Douglas MayersCo-Founder

Scott MorensteinBoard Member

Similar to Antios Therapeutics

Aligos TherapeuticsSan Francisco, CA, USAntivirals, Therapeuticsest. 2018Aligos TherapeuticsSan Francisco, CA, US · est. 2018

Aligos Therapeutics: A leading biopharmaceutical firm specializing in antiviral therapies and liver disease treatment.

Public · $400.6M92

Antiva BiosciencesSouth San Francisco, CA, USAntiviral Therapiesest. 2012Antiva BiosciencesSouth San Francisco, CA, US · est. 2012

Antiva Biosciences, a biopharmaceutical firm, pioneers antiviral therapies targeting HPV, HIV, and more.

Series E · $140.3M24

RetroviroxSan Diego, CA, USAntiviral, Therapiesest. 2008RetroviroxSan Diego, CA, US · est. 2008

RetroVirox, a San Diego-based biotech firm, innovates in antiviral treatments and offers cell-based screening services.

Anthos TherapeuticsCambridge, MA, USBiopharmaceuticalsest. 2018Anthos TherapeuticsCambridge, MA, US · est. 2018

Anthos Therapeutics: Advancing CVM disease care through innovative, validated biopharmaceutical therapies.

Series A · $250M33

Nicole Vitullo's Similar Executives & Operators

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Lau Eng BoonBoard Member · Bukalapak

Chi-hyung SongBoard Member · Dunamu

WILL WEI CHENGBoard Member · DiDi

Dhirubhai H. AmbaniBoard Member · Reliance Retail

Mason YeoBoard Member · Kakao

JaeHong ChoiBoard Member · Kakao

People Similar to Nicole Vitullo

Michael BartholomewBoard Member · Achelios Therapeutics

Adrian AdamsBoard Member · AcelRx Pharmaceuticals

Niall O'DonnellBoard Member · Spruce Biosciences

Dan JanneyBoard Member · Krystal Biotech

William D. WaddillBoard Member · Arrowhead Pharmaceuticals

B. Lynne ParshallBoard Member · Ionis Pharmaceuticals